

Acute myeloid leukemia with myelodysplasia-related molecular pattern with high frequency of *ASXL1*

American Journal of Hematology

87, 659-662

DOI: 10.1002/ajh.23211

Citation Report

#	ARTICLE	IF	CITATIONS
2	Acute myeloid leukemia: advances in diagnosis and classification. <i>International Journal of Laboratory Hematology</i> , 2013, 35, 358-366.	1.3	41
3	Is it time for 5-azacytidine combinations in high-risk myelodysplastic syndrome patients?. <i>Expert Review of Hematology</i> , 2013, 6, 39-42.	2.2	0
4	Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia. <i>Modern Pathology</i> , 2013, 26, 751-761.	5.5	39
5	The mutational landscape of chromatin regulatory factors across 4,623 tumor samples. <i>Genome Biology</i> , 2013, 14, r106.	9.6	102
6	CD105 (Endoglin) Is Highly Overexpressed in a Subset of Cases of Acute Myeloid Leukemias. <i>American Journal of Clinical Pathology</i> , 2013, 140, 370-378.	0.7	17
7	Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?. <i>Haematologica</i> , 2013, 98, 10-22.	3.5	21
8	Normal-Karyotype Acute Myeloid Leukemia. , 2014, , 1644-1663.		1
9	NPM1 Gene Type A Mutation in Bulgarian Adults with Acute Myeloid Leukemia: A Single-Institution Study. <i>Turkish Journal of Haematology</i> , 2014, 31, 40-48.	0.5	8
10	Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation. <i>Haematologica</i> , 2014, 99, 276-281.	3.5	119
11	Acute myeloid leukemia with DNMT3A mutations. <i>Leukemia and Lymphoma</i> , 2014, 55, 2002-2012.	1.3	17
12	Acute myeloid leukaemia with myelodysplastic features in children: a report of Japanese Paediatric Leukaemia/Lymphoma Study Group. <i>British Journal of Haematology</i> , 2014, 167, 80-86.	2.5	19
13	Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1. <i>Annals of Hematology</i> , 2014, 93, 1695-1703.	1.8	25
14	Molecular Genetic Markers in Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2015, 4, 460-478.	2.4	60
15	Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia. <i>Modern Pathology</i> , 2015, 28, 965-976.	5.5	31
16	Update on recurrent genetic aberrations in acute myeloid leukemia. <i>International Journal of Hematologic Oncology</i> , 2015, 4, 179-190.	1.6	1
17	Preferential occurrence of spliceosome mutations in acute myeloid leukemia with preceding myelodysplastic syndrome and/or myelodysplasia morphology. <i>Leukemia and Lymphoma</i> , 2015, 56, 2301-2308.	1.3	11
18	ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group. <i>Haematologica</i> , 2015, 100, 324-330.	3.5	86
19	Acute Myeloid Leukemia With t(v;5q33) Is Associated With Poor Overall Survival and Often Lacks Myelodysplastic Features. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S85-S90.	0.4	1

#	ARTICLE	IF	CITATIONS
20	Prior cytopenia predicts worse clinical outcome in acute myeloid leukemia. <i>Leukemia Research</i> , 2015, 39, 1034-1040.	0.8	8
21	Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patients. <i>American Journal of Hematology</i> , 2015, 90, E22-4.	4.1	16
22	Molecular landscape in acute myeloid leukemia: where do we stand in 2016. <i>Cancer Biology and Medicine</i> , 2016, 13, 474.	3.0	9
23	Myelodysplasia-Related Features of Acute Myeloid Leukemia Evolving From Philadelphia-Negative Myeloproliferative Neoplasms. <i>Annals of Laboratory Medicine</i> , 2016, 36, 377-379.	2.5	0
24	Repositioning of bromocriptine for treatment of acute myeloid leukemia. <i>Journal of Translational Medicine</i> , 2016, 14, 261.	4.4	18
25	Differential profile of CDKN1A and TP53 expressions in bone marrow mesenchymal stromal cells from myeloid neoplasms. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016, 38, 368-370.	0.7	2
26	Epidemiology, pathogenesis, and etiology of acute leukemia. , 2016, , 3-13.		8
27	Allogeneic hematopoietic stem cell transplant overcomes poor prognosis of acute myeloid leukemia with myelodysplasia-related changes. <i>Leukemia and Lymphoma</i> , 2016, 57, 76-80.	1.3	19
28	Focusing on frequent ASXL1 mutations in myeloid neoplasms, and considering rarer ASXL2 and ASXL3 mutations. <i>Current Medical Research and Opinion</i> , 2017, 33, 781-782.	1.9	8
30	Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. <i>Cancer</i> , 2017, 123, 3050-3060.	4.1	47
31	Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia. <i>Experimental Hematology</i> , 2017, 54, 40-50.	0.4	28
32	Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia. <i>Frontiers in Pharmacology</i> , 2017, 8, 897.	3.5	13
33	Molecular Mutations and Their Cooccurrences in Cytogenetically Normal Acute Myeloid Leukemia. <i>Stem Cells International</i> , 2017, 2017, 1-11.	2.5	43
34	The uniqueness of morphological features of pure erythroid leukemia in myeloid neoplasm with erythroid predominance: A reassessment using criteria revised in the 2016 World Health Organization classification. <i>PLoS ONE</i> , 2017, 12, e0172029.	2.5	3
35	Changes in the World Health Organization 2016 classification of myeloid neoplasms everyone should know. <i>Current Opinion in Hematology</i> , 2018, 25, 120-128.	2.5	4
36	ASXL1 mutations in myeloid neoplasms: pathogenetic considerations, impact on clinical outcomes and survival. <i>Current Medical Research and Opinion</i> , 2018, 34, 757-763.	1.9	21
37	Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era. <i>PLoS ONE</i> , 2018, 13, e0204218.	2.5	23
38	Acute Myeloid Leukemia. , 2018, , 429-466.e5.		6

#	ARTICLE	IF	CITATIONS
39	Determining the frequency of iron overload at diagnosis in de novo acute myeloid leukemia patients with multilineage dysplasia or myelodysplasia-related changes: a case control study. <i>Journal of Hematopathology</i> , 2019, 12, 135-141.	0.4	0
40	Challenges in the diagnosis and treatment of secondary acute myeloid leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 6-13.	4.4	16
41	Upfront allogeneic hematopoietic cell transplantation (HCT) versus remission induction chemotherapy followed by allogeneic HCT for acute myeloid leukemia with multilineage dysplasia: A propensity score matched analysis. <i>American Journal of Hematology</i> , 2019, 94, 103-110.	4.1	8
42	Prognostic Markers of Myelodysplastic Syndromes. <i>Medicina (Lithuania)</i> , 2020, 56, 376.	2.0	10
43	Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC). <i>American Journal of Clinical Pathology</i> , 2020, 154, 731-741.	0.7	22
44	<i>ASXL1</i> mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype. <i>Cancer Medicine</i> , 2020, 9, 3637-3646.	2.8	14
45	Secondary Acute Myeloid Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 449-463.	2.2	17
46	Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes. <i>American Journal of Clinical Pathology</i> , 2020, 153, 656-663.	0.7	11
47	Expression profiling of some Acute Myeloid Leukemia - associated markers to assess their diagnostic / prognostic potential. <i>Genetics and Molecular Biology</i> , 2021, 44, e20190268.	1.3	4
48	Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. <i>Blood Advances</i> , 2021, 5, 1719-1728.	5.2	13
49	Emerging therapies for AML with myelodysplasia-related changes: slowly but surely moving the needle. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 245-257.	2.4	1
50	Myeloid malignancies with translocation t(4;12)(q11;q13;p13): molecular landscape, clonal hierarchy and clinical outcomes. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 9557-9566.	3.6	2
51	Distinct Mutation Landscapes Between Acute Myeloid Leukemia With Myelodysplasia-Related Changes and De Novo Acute Myeloid Leukemia. <i>American Journal of Clinical Pathology</i> , 2022, 157, 691-700.	0.7	22
52	Myelodysplastic syndromes are induced by histone methylation-altering ASXL1 mutations. <i>Journal of Clinical Investigation</i> , 2013, 123, 4627-4640.	8.2	140
53	Role of <i>ASXL1</i> and <i>TP53</i> mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. <i>Oncotarget</i> , 2015, 6, 8388-8396.	1.8	69
54	The Progress of Next Generation Sequencing in the Assessment of Myeloid Malignancies. <i>Balkan Medical Journal</i> , 2019, 36, 78-87.	0.8	3
55	Advances in acute myeloid leukemia. <i>BMJ, The</i> , 2021, 375, n2026.	6.0	177
56	Nucleophosmin (NPM1)., 2015, , 251-273.		0

#	ARTICLE	IF	CITATIONS
57	Acute Myeloid Leukemia With Myelodysplasia-Related Changes. , 2018, , 662-667.		0
58	Acute Myeloid Neoplasms. , 2020, , 207-233.		0
59	Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients. <i>Cancers</i> , 2022, 14, 2025.	3.7	17
61	Genetic Characteristics According to Subgroup of Acute Myeloid Leukemia with Myelodysplasia-Related Changes. <i>Journal of Clinical Medicine</i> , 2022, 11, 2378.	2.4	6
62	Hematopoyesis Clonal de Potencial Indeterminado (HCPI): mÃ¡s allÃ¡ de un modelo de campo de cancerizaciÃ³n. <i>Revista Colombiana De CancerologÃa</i> , 2021, 25, 210-221.	0.2	0
63	Acute myeloid leukemia with myelodysplasia-related changes and blasts of the mixed T/myeloid phenotype: a case report. <i>Journal of International Medical Research</i> , 2022, 50, 030006052211227.	1.0	1
64	Updates in molecular genetics of acute myeloid leukemia. <i>Seminars in Diagnostic Pathology</i> , 2023, , .	1.5	1
65	Analysis and clinical characteristics of acute myeloid leukemia developing with prior or concurrent tumors in non cyto- or radiotherapy exposure patients in a single center. <i>Hematology</i> , 2023, 28, .	1.5	0
66	Case report: Positive response to venetoclax and azacitidine in the treatment of acute myeloid leukemia with myelodysplasia-related changes and blasts of the mixed T/myeloid phenotype. <i>Pediatric Blood and Cancer</i> , 2023, 70, .	1.5	1
67	Assessment of 2022 European LeukemiaNet risk classification system in real-world cohort from China. <i>Cancer Medicine</i> , 2023, 12, 21615-21626.	2.8	0